Has any formal cost-effectiveness study been published specifically on the Bunevicius T4+T3 protocol?

No. As of 2025, no peer-reviewed publication presents a formal CEA using the Bunevicius trial data as the efficacy input. Economic estimates must be constructed from drug pricing and utility-mapping techniques applied to the reported mood outcomes.

How much does adding liothyronine cost per month in the US?

Generic liothyronine costs $25, $90/month at retail depending on dose and pharmacy. Discount platforms reduce this to $25, $45 for typical doses. Brand Cytomel exceeds $150/month. Compounded sustained-release T3 costs $40, $80/month.

Is combination T4+T3 therapy covered by insurance?

Coverage is inconsistent. Some plans cover generic liothyronine with a prior authorization demonstrating T4 monotherapy failure. Many commercial and Medicare Part D plans exclude it or place it on high-cost tiers. No US payer covers compounded T3 preparations.

What is the estimated cost per QALY for T4+T3 combination therapy?

Depending on drug source and response magnitude, estimates range from $3,400/QALY (best case) to $68,000/QALY (worst case). The realistic range for a generic-using insured patient is $7,200, $24,000/QALY, which falls below standard US willingness-to-pay thresholds.

Why do payers deny coverage if the ICER is acceptable?

Three factors: the small evidence base (N=33 in the key trial, non-replication in larger studies), volatile generic pricing that complicates formulary budgeting, and the absence of an FDA-approved fixed-dose combination product.

Does the DIO2 gene polymorphism affect the economic calculation?

Potentially. If DIO2 Thr92Ala carriers respond preferentially to combination therapy, targeting this 16% subgroup would concentrate QALY gains and improve the ICER. No prospective pharmacoeconomic study has tested this hypothesis, though the THYRAM trial (ongoing) may provide data.

How long should a patient trial combination therapy before deciding it works?

The Bunevicius crossover used 5-week periods. This provides a reasonable minimum trial duration. Patients who notice no cognitive or mood improvement by 5 weeks are unlikely to benefit from longer exposure based on the available kinetic and clinical data.

Is compounded sustained-release T3 more cost-effective than immediate-release?

No economic comparison exists. Compounded T3 costs $40, $80/month (never covered by insurance) versus $25, $45/month for generic immediate-release (sometimes covered). If sustained-release formulations produce more stable T3 levels and better outcomes, their higher cost could be offset. This remains unproven.

How does T4+T3 cost-effectiveness compare to other thyroid interventions?

TSH screening costs $5,000, $15,000/QALY. Treating subclinical hypothyroidism costs $2,000, $8,000/QALY. Combination T4+T3 at $7,200, $24,000/QALY sits in a comparable range but carries more evidentiary uncertainty.

Could a fixed-dose T4+T3 combination product change the economics?

Yes. A single-tablet combination would reduce pharmacy dispensing costs, eliminate dual copays, simplify prior authorization, and likely achieve formulary placement more readily. Several companies have explored development but none have reached FDA approval as of 2025.

Bunevicius T4+T3 Cost, Cost-Effectiveness, and Health-Economic Implications

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

What Does Combination T4+T3 Therapy Actually Cost, and Is It Worth It?

At a glance

| Parameter | Detail | |-----------|--------| | N | 33 (crossover design) | | Intervention | Levothyroxine dose reduced by 50 mcg + liothyronine 12.5 mcg | | Comparator | Levothyroxine monotherapy (usual dose) | | Duration | 5 weeks per crossover period | | Primary endpoint | Composite cognitive, mood, and quality-of-life battery | | Key result | T4/T3 combination superior on multiple neuropsychological measures (Bunevicius et al., 1999) |

The Economic Gap in the Original Trial

The 1999 Bunevicius study was designed as a proof-of-concept crossover trial with 33 patients. It reported statistically significant improvements in Profile of Mood States scores, visual scanning speed, and Symptom Checklist-90 measures during the combination phase. What it did not report, and was never designed to report, was any economic endpoint. No cost data were collected. No utility weights were assigned to the mood improvements. No willingness-to-pay threshold was discussed.

This absence matters because the trial became the foundational citation for a clinical debate that now spans over two decades. Patients and clinicians wanting to act on the Bunevicius findings must construct their own value assessment from scratch.

A Framework for Modeling T4+T3 Cost-Effectiveness

Because no published formal cost-effectiveness analysis (CEA) exists specifically for the Bunevicius protocol, the following framework synthesizes available drug-pricing data, utility estimates from thyroid quality-of-life literature, and standard health-economic methodology.

Drug Acquisition Costs (2025 US Pricing)

| Component | Monthly AWP (brand) | Monthly AWP (generic) | Typical net price after rebate | |-----------|--------------------|-----------------------|-------------------------------| | Levothyroxine 100 mcg/day | $45, $65 (Synthroid) | $4, $15 | $4, $12 | | Liothyronine 12.5 mcg/day (split from 25 mcg tablets) | $120, $180 (Cytomel) | $30, $90 | $25, $70 | | Combination total | $165, $245 | $34, $105 | $29, $82 | | Monotherapy baseline | $45, $65 | $4, $15 | $4, $12 |

The incremental monthly cost of adding liothyronine ranges from $17 (best-case generic, GoodRx-discounted) to $170 (brand Cytomel, cash pay). Annualized, the incremental spend is $204 to $2,040. These figures come from FDA-approved labeling for Cytomel cross-referenced with pharmacy benefit manager published rates.

Utility Estimation

The Bunevicius trial used categorical mood and cognitive instruments rather than preference-based utility measures like the EQ-5D. To estimate QALYs gained, one must map the observed effect sizes to utility decrements.

Hypothyroid patients on adequate T4 monotherapy report baseline utilities of approximately 0.78, 0.82 on the EQ-5D, based on cross-sectional data from UK and Dutch thyroid registries. The mood improvements seen in Bunevicius et al. correspond roughly to a 0.03, 0.06 utility increment, using validated depression-to-utility mapping algorithms (Brazier et al., 2002).

Over one year, this translates to 0.03, 0.06 QALYs gained.

Incremental Cost-Effectiveness Ratio (ICER)

| Scenario | Annual incremental cost | QALY gain | ICER ($/QALY) | |----------|------------------------|-----------|---------------| | Best case (generic T3, high responder) | $204 | 0.06 | $3,400 | | Middle estimate (generic T3, average responder) | $600 | 0.04 | $15,000 | | Worst case (brand T3, modest responder) | $2,040 | 0.03 | $68,000 | | Realistic insured patient | $360, $840 | 0.035, 0.05 | $7,200, $24,000 |

At a $50,000/QALY threshold commonly used in US payer decisions, combination therapy falls below the threshold in most scenarios except brand-name Cytomel with minimal clinical response.

Why Payers Still Deny Coverage

Despite potentially acceptable ICERs, formulary coverage for liothyronine remains inconsistent. Three structural barriers explain this disconnect.

First, the evidence base remains thin. The Bunevicius trial enrolled only 33 patients for 5 weeks per arm. Subsequent larger trials (Saravanan et al., 2005; Appelhof et al., 2005) failed to replicate the cognitive benefits in intention-to-treat analyses, though post-hoc subgroups and patient-preference data remained positive. The American Thyroid Association 2014 guidelines acknowledged combination therapy as experimental, recommending against routine use while leaving room for individual trials.

Second, generic liothyronine pricing is volatile. Between 2017 and 2023, the number of US generic manufacturers fluctuated between two and four, producing price swings of 300% in some quarters. Pharmacy benefit managers build formularies around price predictability. A drug whose cost can triple between contract renewals gets classified as "specialty-adjacent" even when its absolute cost is low.

Third, no FDA-approved combination product exists. Each prescription requires two separate fills, two copays, and two prior authorization pathways in many plans. The administrative friction alone reduces uptake independent of clinical merit.

List Price vs. Net Price: What Patients Actually Pay

The gap between list and net pricing for thyroid medications is smaller than for biologics but still meaningful.

For levothyroxine, the generic market is commoditized. Most insured patients pay $0, $10/month. Cash-pay patients using discount programs pay $4, $8/month.

For liothyronine, the picture is more complex. Brand Cytomel carries a list price exceeding $150/month for common doses. Generic liothyronine 5 mcg tablets (the only available strength besides 25 mcg and 50 mcg) range from $30 to $90/month at retail, but discount platforms frequently offer 30-day supplies at $25, $45. Compounded sustained-release T3 preparations, which some clinicians prefer for more stable serum levels, cost $40, $80/month from accredited pharmacies but are not covered by any commercial plan.

For an uninsured patient replicating the Bunevicius protocol (reducing T4 by 50 mcg, adding 12.5 mcg T3), the realistic monthly out-of-pocket is $30, $55 for both medications combined using generic sources.

The Individual Value Calculation

Cost-effectiveness at the population level and value to an individual patient are different questions. A patient with persistent cognitive complaints despite optimized TSH on levothyroxine faces a specific decision matrix.

Variables that increase individual value:

Documented DIO2 polymorphism (Thr92Ala), present in approximately 16% of the population, which may impair local T4-to-T3 conversion
Persistent fatigue or cognitive complaints with TSH 0.5, 2.0 on monotherapy
Low-normal free T3 despite adequate free T4
Failed trial of dose optimization, iron repletion, and sleep hygiene

Variables that decrease individual value:

Symptoms explained by comorbid depression, sleep apnea, or anemia
Cardiac history or atrial fibrillation risk (T3 peaks increase arrhythmia susceptibility)
Inability to split doses (T3's short half-life of 1 to 2.5 days means BID dosing improves stability)
Cost sensitivity exceeding $40/month without insurance coverage

The Bunevicius protocol itself provides a natural "trial duration" benchmark: 5 weeks is sufficient to assess subjective response. If a patient notices no improvement in mood or cognition after 5 weeks on the combination, the probability of late response is low based on the crossover data, and discontinuation is appropriate.

Limitations of Any Economic Model Applied to This Trial

Several methodological constraints make formal CEA difficult to apply to the Bunevicius data:

Crossover contamination of utility measurement. In a crossover design, period effects and carryover bias can inflate treatment differences. Utility gains estimated from crossover data may not persist in parallel-group long-term use.
Five-week duration. QALYs are annual constructs. Extrapolating 5-week mood improvements to annual utility gains assumes persistence of benefit, which has not been demonstrated in any long-term combination therapy trial.
Sample size of 33. Confidence intervals around the treatment effect are wide. The ICER confidence region likely spans from cost-saving to cost-ineffective depending on which end of the effect-size CI one uses.
No direct comparator for sustained-release T3. The Bunevicius trial used immediate-release liothyronine. Many current prescribers use compounded sustained-release formulations, which have different pharmacokinetics and costs. The economic model cannot directly apply to these preparations.
Absence of long-term safety cost offsets. If combination therapy reduces antidepressant use or improves work productivity, downstream cost savings could shift the ICER favorably. No data quantify these offsets.

Comparison to Other Thyroid Economic Interventions

For context, TSH screening in the general population carries an ICER of approximately $5,000, $15,000/QALY (Danese et al., 1996). Treatment of subclinical hypothyroidism in symptomatic patients costs roughly $2,000, $8,000/QALY. Combination T4+T3 therapy, even at middle-estimate ICERs, sits in the same economic territory as accepted thyroid interventions, yet receives far less formulary support due to evidentiary uncertainty rather than cost.

Frequently asked questions

›

References

Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med. 1999;340(6):424-429. PubMed
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force. Thyroid. 2014;24(12):1670-1751. PubMed
FDA. Cytomel (liothyronine sodium) prescribing information. Revised 2018. AccessData
Saravanan P, Simmons DJ, Visser TJ, Dayan CM. Randomized controlled trial of combination thyroxine plus triiodothyronine replacement therapy. J Clin Endocrinol Metab. 2005;90(2):805-812. PubMed
Appelhof BC, Fliers E, Wekking EM, et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy. J Clin Endocrinol Metab. 2005;90(5):2666-2674. PubMed
Danese MD, Powe NR, Sawin CT, Ladenson PW. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA. 1996;276(4):285-292. PubMed